• +1-646-491-9876
    • +91-20-67278686

    Search

    Non-Hodgkin Lymphoma-Pipeline Review H1 2017

    Non-Hodgkin Lymphoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834365
    • Category Pharmaceuticals
    • No. of Pages 1740
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

    Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot) ,fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively.

    Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 11
    Non-Hodgkin Lymphoma - Overview 12
    Non-Hodgkin Lymphoma - Therapeutics Development 13
    Non-Hodgkin Lymphoma - Therapeutics Assessment 85
    Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 111
    Non-Hodgkin Lymphoma - Drug Profiles 233
    Non-Hodgkin Lymphoma - Dormant Projects 1656
    Non-Hodgkin Lymphoma - Discontinued Products 1676
    Non-Hodgkin Lymphoma - Product Development Milestones 1684
    Appendix 1692

    List of Tables

    Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017 60
    Number of Products under Development by Companies, H1 2017 62
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 63
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 64
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 65
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 66
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 67
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 68
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 69
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 70
    Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 71
    Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 72
    Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 73
    Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 74
    Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 75
    Number of Products under Development by Universities/Institutes, H1 2017 76
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 77
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 78
    Products under Development by Companies, H1 2017 79
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 80
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 81
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 82
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 83
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 84
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 85
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 86
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 87
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 88
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 89
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 90
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 91
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 92
    Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 93
    Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 94
    Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 95
    Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 96
    Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 97
    Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 98
    Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 99
    Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 100
    Products under Development by Companies, H1 2017 (Contd..22) , H1 2017 101
    Products under Development by Companies, H1 2017 (Contd..23) , H1 2017 102
    Products under Development by Companies, H1 2017 (Contd..24) , H1 2017 103
    Products under Development by Companies, H1 2017 (Contd..25) , H1 2017 104
    Products under Development by Companies, H1 2017 (Contd..26) , H1 2017 105
    Products under Development by Companies, H1 2017 (Contd..27) , H1 2017 106
    Products under Development by Companies, H1 2017 (Contd..28) , H1 2017 107
    Products under Development by Companies, H1 2017 (Contd..29) , H1 2017 108
    Products under Development by Companies, H1 2017 (Contd..30) , H1 2017 109
    Products under Development by Companies, H1 2017 (Contd..31) , H1 2017 110
    Products under Development by Companies, H1 2017 (Contd..32) , H1 2017 111
    Products under Development by Companies, H1 2017 (Contd..33) , H1 2017 112
    Products under Development by Companies, H1 2017 (Contd..34) , H1 2017 113
    Products under Development by Companies, H1 2017 (Contd..35) , H1 2017 114
    Products under Development by Companies, H1 2017 (Contd..36) , H1 2017 115
    Products under Development by Companies, H1 2017 (Contd..37) , H1 2017 116
    Products under Development by Companies, H1 2017 (Contd..38) , H1 2017 117
    Products under Development by Companies, H1 2017 (Contd..39) , H1 2017 118
    Products under Development by Companies, H1 2017 (Contd..40) , H1 2017 119
    Products under Development by Companies, H1 2017 (Contd..41) , H1 2017 120
    Products under Development by Companies, H1 2017 (Contd..42) , H1 2017 121
    Products under Development by Companies, H1 2017 (Contd..43) , H1 2017 122
    Products under Development by Companies, H1 2017 (Contd..44) , H1 2017 123
    Products under Development by Companies, H1 2017 (Contd..45) , H1 2017 124
    Products under Development by Companies, H1 2017 (Contd..46) , H1 2017 125
    Products under Development by Companies, H1 2017 (Contd..47) , H1 2017 126
    Products under Development by Universities/Institutes, H1 2017 127
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 128
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 129
    Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 131
    Number of Products by Stage and Target, H1 2017 133
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 134
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 135
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 136
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 137
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 138
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 139
    Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 140
    Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017 141
    Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017 142
    Number of Products by Stage and Mechanism of Action, H1 2017 144
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 145
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 146
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 147
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 148
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 149
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 150
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 151
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017 152
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9) , H1 2017 153
    Number of Products by Stage and Route of Administration, H1 2017 155
    Number of Products by Stage and Molecule Type, H1 2017 157
    Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H1 2017 158
    Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2017 158
    Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2017 159
    Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H1 2017 160
    Non-Hodgkin Lymphoma - Pipeline by ACEA Biosciences Inc, H1 2017 162
    Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H1 2017 162
    Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2017 163
    Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H1 2017 164
    Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H1 2017 164
    Non-Hodgkin Lymphoma - Pipeline by Aileron Therapeutics Inc, H1 2017 165
    Non-Hodgkin Lymphoma - Pipeline by Alfa Wassermann SpA, H1 2017 165
    Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2017 166
    Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corp, H1 2017 166
    Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H1 2017 167
    Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2017 168
    Non-Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc, H1 2017 168
    Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2017 169
    Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics Inc, H1 2017 169
    Non-Hodgkin Lymphoma - Pipeline by ArQule Inc, H1 2017 170
    Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H1 2017 170
    Non-Hodgkin Lymphoma - Pipeline by Arven Ilac, H1 2017 171
    Non-Hodgkin Lymphoma - Pipeline by Arvinas Inc, H1 2017 171
    Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences LLC, H1 2017 172
    Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H1 2017 172
    Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017 173
    Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2017 173
    Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics Inc, H1 2017 174
    Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 174
    Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2017 175
    Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, H1 2017 177
    Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 177
    Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings Inc, H1 2017 178
    Non-Hodgkin Lymphoma - Pipeline by BioAtla LLC, H1 2017 178
    Non-Hodgkin Lymphoma - Pipeline by Biocon Ltd, H1 2017 179
    Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2017 179
    Non-Hodgkin Lymphoma - Pipeline by BioLineRx Ltd, H1 2017 180
    Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2017 180
    Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H1 2017 181
    Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd, H1 2017 181
    Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017 182
    Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 182
    Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical Inc, H1 2017 183
    Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2017 183
    Non-Hodgkin Lymphoma - Pipeline by Calimmune Inc, H1 2017 184
    Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences Inc, H1 2017 184
    Non-Hodgkin Lymphoma - Pipeline by Cascadian Therapeutics Inc, H1 2017 185
    Non-Hodgkin Lymphoma - Pipeline by Celgene Corp, H1 2017 186
    Non-Hodgkin Lymphoma - Pipeline by Cell Medica Ltd, H1 2017 188
    Non-Hodgkin Lymphoma - Pipeline by Cell Source Inc, H1 2017 188
    Non-Hodgkin Lymphoma - Pipeline by Cell>Point LLC, H1 2017 189
    Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics Inc, H1 2017 189
    Non-Hodgkin Lymphoma - Pipeline by Cellectar Biosciences Inc, H1 2017 190
    Non-Hodgkin Lymphoma - Pipeline by Cellectis SA, H1 2017 191
    Non-Hodgkin Lymphoma - Pipeline by Celleron Therapeutics Ltd, H1 2017 191
    Non-Hodgkin Lymphoma - Pipeline by Celltrion Inc, H1 2017 192
    Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group Inc, H1 2017 193
    Non-Hodgkin Lymphoma - Pipeline by Celon Pharma SA, H1 2017 194
    Non-Hodgkin Lymphoma - Pipeline by Centrose LLC, H1 2017 194
    Non-Hodgkin Lymphoma - Pipeline by CerRx Inc, H1 2017 195
    Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017 195
    Non-Hodgkin Lymphoma - Pipeline by Cleave Biosciences Inc, H1 2017 196
    Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SAS, H1 2017 196
    Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences Inc, H1 2017 197
    Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 197
    Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017 198
    Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017 198
    Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp, H1 2017 199
    Non-Hodgkin Lymphoma - Pipeline by Curis Inc, H1 2017 200
    Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017 201
    Non-Hodgkin Lymphoma - Pipeline by CytomX Therapeutics Inc, H1 2017 201
    Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 202
    Non-Hodgkin Lymphoma - Pipeline by Debiopharm International SA, H1 2017 202
    Non-Hodgkin Lymphoma - Pipeline by Denovo Biopharma LLC, H1 2017 203
    Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corp, H1 2017 203
    Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017 204
    Non-Hodgkin Lymphoma - Pipeline by Eisai Co Ltd, H1 2017 204
    Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2017 205
    Non-Hodgkin Lymphoma - Pipeline by EpiZyme Inc, H1 2017 206
    Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2017 207
    Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H1 2017 207
    Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 208
    Non-Hodgkin Lymphoma - Pipeline by Forma Therapeutics Inc, H1 2017 209
    Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals Inc, H1 2017 209
    Non-Hodgkin Lymphoma - Pipeline by Forty Seven Inc, H1 2017 210
    Non-Hodgkin Lymphoma - Pipeline by Galderma SA, H1 2017 210
    Non-Hodgkin Lymphoma - Pipeline by Genentech Inc, H1 2017 211
    Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H1 2017 212
    Non-Hodgkin Lymphoma - Pipeline by Genosco Inc, H1 2017 212
    Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences Inc, H1 2017 213
    Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2017 214
    Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional SA, H1 2017 214
    Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc, H1 2017 215
    Non-Hodgkin Lymphoma - Pipeline by Heidelberg Pharma GmbH, H1 2017 215
    Non-Hodgkin Lymphoma - Pipeline by Humorigin Biotechnology Corp, H1 2017 216
    Non-Hodgkin Lymphoma - Pipeline by Hutchison China MediTech Ltd, H1 2017 216
    Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2017 217
    Non-Hodgkin Lymphoma - Pipeline by IGF Oncology LLC, H1 2017 217
    Non-Hodgkin Lymphoma - Pipeline by Ignyta Inc, H1 2017 218
    Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp, H1 2017 218
    Non-Hodgkin Lymphoma - Pipeline by ImmunGene Inc, H1 2017 219
    Non-Hodgkin Lymphoma - Pipeline by ImmunoGen Inc, H1 2017 219
    Non-Hodgkin Lymphoma - Pipeline by Immunomedics Inc, H1 2017 220
    Non-Hodgkin Lymphoma - Pipeline by Immunovaccine Inc, H1 2017 221
    Non-Hodgkin Lymphoma - Pipeline by Immunwork Inc, H1 2017 221
    Non-Hodgkin Lymphoma - Pipeline by Incyte Corp, H1 2017 222
    Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Ltd, H1 2017 223
    Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H1 2017 223
    Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics Inc, H1 2017 224
    Non-Hodgkin Lymphoma - Pipeline by Japan Tobacco Inc, H1 2017 224
    Non-Hodgkin Lymphoma - Pipeline by JHL Biotech Inc, H1 2017 225
    Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2017 225
    Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc, H1 2017 226
    Non-Hodgkin Lymphoma - Pipeline by K-Stemcell Co Ltd, H1 2017 227
    Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine Inc, H1 2017 227
    Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 228
    Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H1 2017 229
    Non-Hodgkin Lymphoma - Pipeline by Klyss Biotech Inc, H1 2017 230
    Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co Ltd, H1 2017 230
    Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 231
    Non-Hodgkin Lymphoma - Pipeline by LFB SA, H1 2017 231
    Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2017 232
    Non-Hodgkin Lymphoma - Pipeline by MacroGenics Inc, H1 2017 233
    Non-Hodgkin Lymphoma - Pipeline by MedImmune LLC, H1 2017 233
    Non-Hodgkin Lymphoma - Pipeline by Medivir AB, H1 2017 234
    Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, H1 2017 234
    Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, H1 2017 235
    Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, H1 2017 236
    Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2017 237
    Non-Hodgkin Lymphoma - Pipeline by Mesoblast Ltd, H1 2017 238
    Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 239
    Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics Inc, H1 2017 240
    Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc, H1 2017 240
    Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc, H1 2017 241
    Non-Hodgkin Lymphoma - Pipeline by Moleculin Biotech Inc, H1 2017 241
    Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd, H1 2017 242
    Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2017 242
    Non-Hodgkin Lymphoma - Pipeline by NantKwest Inc, H1 2017 243
    Non-Hodgkin Lymphoma - Pipeline by NBE-Therapeutics AG, H1 2017 243
    Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc, H1 2017 244
    Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2017 244
    Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017 245
    Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2017 246
    Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2017 246
    Non-Hodgkin Lymphoma - Pipeline by Oncobiologics Inc, H1 2017 247
    Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics Inc, H1 2017 247
    Non-Hodgkin Lymphoma - Pipeline by Oncopeptides AB, H1 2017 248
    Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc, H1 2017 248
    Non-Hodgkin Lymphoma - Pipeline by Oncovir Inc, H1 2017 249
    Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics Inc, H1 2017 249
    Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 250
    Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2017 251
    Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2017 251
    Non-Hodgkin Lymphoma - Pipeline by OXIS International Inc, H1 2017 253
    Non-Hodgkin Lymphoma - Pipeline by Patrys Ltd, H1 2017 253
    Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc, H1 2017 254
    Non-Hodgkin Lymphoma - Pipeline by Pharma Mar SA, H1 2017 254
    Non-Hodgkin Lymphoma - Pipeline by Philogen SpA, H1 2017 255
    Non-Hodgkin Lymphoma - Pipeline by PIQUR Therapeutics AG, H1 2017 255
    Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017 255
    Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals Inc, H1 2017 256
    Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd, H1 2017 256
    Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 257
    Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2017 257
    Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 258
    Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt, H1 2017 258
    Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2017 259
    Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2017 259
    Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2017 260
    Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics Inc, H1 2017 261
    Non-Hodgkin Lymphoma - Pipeline by Selvita SA, H1 2017 262
    Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences Inc, H1 2017 262
    Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017 263
    Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017 263
    Non-Hodgkin Lymphoma - Pipeline by Sierra Oncology Inc, H1 2017 264
    Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau SpA, H1 2017 264
    Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H1 2017 265
    Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma KK, H1 2017 265
    Non-Hodgkin Lymphoma - Pipeline by Soligenix Inc, H1 2017 266
    Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics Inc, H1 2017 266
    Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017 267
    Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics Inc, H1 2017 268
    Non-Hodgkin Lymphoma - Pipeline by Sunesis Pharmaceuticals Inc, H1 2017 269
    Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc, H1 2017 269
    Non-Hodgkin Lymphoma - Pipeline by Surface Oncology Inc, H1 2017 270
    Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma Inc, H1 2017 270
    Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 270
    Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017 271
    Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc, H1 2017 271
    Non-Hodgkin Lymphoma - Pipeline by Targazyme Inc, H1 2017 272
    Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 272
    Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics Inc, H1 2017 273
    Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2017 273
    Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 274
    Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Ltd, H1 2017 274
    Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H1 2017 275
    Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc, H1 2017 275
    Non-Hodgkin Lymphoma - Pipeline by United BioPharma Inc, H1 2017 276
    Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics Inc, H1 2017 276
    Non-Hodgkin Lymphoma - Pipeline by Verastem Inc, H1 2017 277
    Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2017 277
    Non-Hodgkin Lymphoma - Pipeline by Xencor Inc, H1 2017 278
    Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences Inc, H1 2017 278
    Non-Hodgkin Lymphoma - Pipeline by ZIOPHARM Oncology Inc, H1 2017 279
    Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc, H1 2017 279
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 1703
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017 1704
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..2) , H1 2017 1705
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..3) , H1 2017 1706
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..4) , H1 2017 1707
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..5) , H1 2017 1708
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..6) , H1 2017 1710
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..7) , H1 2017 1711
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..8) , H1 2017 1712
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..9) , H1 2017 1713
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..10) , H1 2017 1714
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..11) , H1 2017 1715
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..12) , H1 2017 1716
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..13) , H1 2017 1717
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..14) , H1 2017 1718
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..15) , H1 2017 1719
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..16) , H1 2017 1720
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..17) , H1 2017 1721
    Non-Hodgkin Lymphoma - Dormant Projects, H1 2017 (Contd..18) , H1 2017 1722
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 1723
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..1) , H1 2017 1724
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..2) , H1 2017 1725
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..3) , H1 2017 1726
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..4) , H1 2017 1727
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..5) , H1 2017 1728
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..6) , H1 2017 1729
    Non-Hodgkin Lymphoma - Discontinued Products, H1 2017 (Contd..7) , H1 2017 1730



    List of Figures

    Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017 60
    Number of Products under Development by Companies, H1 2017 61
    Number of Products under Development by Universities/Institutes, H1 2017 76
    Number of Products by Top 10 Targets, H1 2017 132
    Number of Products by Stage and Top 10 Targets, H1 2017 132
    Number of Products by Top 10 Mechanism of Actions, H1 2017 143
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 143
    Number of Products by Top 10 Routes of Administration, H1 2017 154
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017 154
    Number of Products by Top 10 Molecule Types, H1 2017 156
    Number of Products by Stage and Top 10 Molecule Types, H1 2017 156
    3SBio Inc
    4SC AG
    AB Science SA
    AbbVie Inc
    ACEA Biosciences Inc
    Actinium Pharmaceuticals Inc
    ADC Therapeutics Sarl
    Affimed GmbH
    Affitech A/S
    Aileron Therapeutics Inc
    Alfa Wassermann SpA
    Allinky Biopharma
    Altor BioScience Corp
    Amgen Inc
    Angimmune LLC
    Aptose Biosciences Inc
    arGEN-X BV
    Arno Therapeutics Inc
    ArQule Inc
    Arrien Pharmaceuticals LLC
    Arven Ilac
    Arvinas Inc
    Asana BioSciences LLC
    Astellas Pharma Inc
    Astex Pharmaceuticals Inc
    AstraZeneca Plc
    Atara Biotherapeutics Inc
    Aurigene Discovery Technologies Ltd
    Bayer AG
    BeiGene Ltd
    Bellicum Pharmaceuticals Inc
    Bio-Path Holdings Inc
    BioAtla LLC
    Biocon Ltd
    BioInvent International AB
    BioLineRx Ltd
    Bionovis SA
    BioNTech AG
    BioSight Ltd
    Biothera Pharmaceutical Inc
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Calimmune Inc
    Calithera Biosciences Inc
    Cascadian Therapeutics Inc
    Celgene Corp
    Cell Medica Ltd
    Cell Source Inc
    Cell>Point LLC
    Celldex Therapeutics Inc
    Cellectar Biosciences Inc
    Cellectis SA
    Celleron Therapeutics Ltd
    Celltrion Inc
    Cellular Biomedicine Group Inc
    Celon Pharma SA
    Centrose LLC
    CerRx Inc
    Chipscreen Biosciences Ltd
    Cleave Biosciences Inc
    Clevexel Pharma SAS
    Coherus BioSciences Inc
    Constellation Pharmaceuticals Inc
    Cornerstone Pharmaceuticals Inc
    CSPC Pharmaceutical Group Limited
    CTI BioPharma Corp
    Curis Inc
    Cyclacel Pharmaceuticals Inc
    CytomX Therapeutics Inc
    Daiichi Sankyo Company Ltd
    Debiopharm International SA
    Denovo Biopharma LLC
    Dynavax Technologies Corp
    eFFECTOR Therapeutics Inc
    Eisai Co Ltd
    Eli Lilly and Company
    EpiZyme Inc
    Erytech Pharma SA
    Evotec AG
    F. Hoffmann-La Roche Ltd
    Forma Therapeutics Inc
    Formula Pharmaceuticals Inc
    Forty Seven Inc
    Galderma SA
    Genentech Inc
    Genor BioPharma Co Ltd
    Genosco Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Grupo Ferrer Internacional SA
    H3 Biomedicine Inc
    Heidelberg Pharma GmbH
    Humorigin Biotechnology Corp
    Hutchison China MediTech Ltd
    iDD biotech SAS
    IGF Oncology LLC
    Ignyta Inc
    Immune Design Corp
    ImmunGene Inc
    ImmunoGen Inc
    Immunomedics Inc
    Immunovaccine Inc
    Immunwork Inc
    Incyte Corp
    Inflection Biosciences Ltd
    Innate Pharma SA
    Innovent Biologics Inc
    Japan Tobacco Inc
    JHL Biotech Inc
    Johnson & Johnson
    Juno Therapeutics Inc
    K-Stemcell Co Ltd
    Kainos Medicine Inc
    Karyopharm Therapeutics Inc
    Kite Pharma Inc
    Klyss Biotech Inc
    Komipharm International Co Ltd
    Kyowa Hakko Kirin Co Ltd
    LFB SA
    Mabion SA
    MacroGenics Inc
    MedImmune LLC
    Medivir
    AB
    MEI Pharma Inc
    MENTRIK Biotech LLC
    Merck & Co Inc
    Merck KGaA
    Mesoblast Ltd
    Millennium Pharmaceuticals Inc
    miRagen Therapeutics Inc
    Mirati Therapeutics Inc
    Molecular Templates Inc
    Moleculin Biotech Inc
    Molplex Ltd
    MorphoSys AG
    NantKwes
    t Inc
    NBE-Therapeutics AG
    Neumedicines Inc
    Nordic Nanovector ASA
    NovaLead Pharma Pvt Ltd
    Novartis AG
    NovImmune SA
    Oncobiologics Inc
    Onconova Therapeutics Inc
    Oncopeptides AB
    OncoSec Medical Inc
    Oncovir Inc
    Oncternal Therapeutics Inc
    Ono Pharmaceutical Co Ltd
    Onxeo SA
    Oxford BioTherapeutics Ltd
    OXIS International Inc
    Patrys Ltd
    Pfizer Inc
    Pharma Mar SA
    Philogen SpA
    PIQUR Therapeutics AG
    Polaris Pharmaceuticals Inc
    Portola Pharmaceuticals Inc
    RedHill Biopharma Ltd
    Regeneron Pharmaceuticals Inc
    Respiratorius AB
    Rhizen Pharmaceuticals SA
    Richter Gedeon Nyrt
    Sandoz International GmbH
    Sanofi
    Sareum Holdings Plc
    Seattle Genetics Inc
    Selvita SA
    Senhwa Biosciences Inc
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    Shanghai Pharmaceutical Co Ltd
    Sierra Oncology Inc
    Sigma-Tau SpA
    Simcere Pharmaceutical Group
    Solasia Pharma KK
    Soligenix Inc
    Sorrento Therapeutics Inc
    Spectrum Pharmaceuticals Inc
    Stemline Therapeutics Inc
    Sunesis Pharmaceuticals Inc
    Supratek Pharma Inc
    Surface Oncology Inc
    Sutro Biopharma Inc
    Taiho Pharmaceutical Co Ltd
    Taiwan Liposome Company Ltd
    Takara Bio Inc
    Targazyme Inc
    Teva Pharmaceutical Industries Ltd
    TG Therapeutics Inc
    Theravectys SA
    TRACON Pharmaceuticals Inc
    Transgene Biotek Ltd
    Transgene SA
    Trillium Therapeutics Inc
    United BioPharma Inc
    Unum Therapeutics Inc
    Verastem Inc
    Vivolux AB
    Xencor Inc
    Xenetic Biosciences Inc
    ZIOPHARM Oncology Inc
    Zymeworks Inc

    Request for Sample

    Report Url https://www.reportsweb.com//non-hodgkin-lymphoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//non-hodgkin-lymphoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//non-hodgkin-lymphoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments